Phagocytes as Corrupted Policemen in Cancer-Related Inflammation

Advances in Cancer Research

Volumn 128, Issue , 2015, Pages 141-171

  Bonavita, Eduardo ^a   Galdiero, Maria Rosaria ^a,b   Jaillon, Sebastien ^a   Mantovani, Alberto ^a,c  

^a HUMANITAS CLINICAL AND RESEARCH CENTER   (Italy)

^b UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^c Humanits University   (Italy)

Author keywords

Complement; Complement and cancer; Inflammation; Macrophages; Neutrophils; PTX3; Tumor associated macrophages

Indexed keywords

ANGIOTENSIN II; ANTINEOPLASTIC AGENT; ARGINASE 1; C REACTIVE PROTEIN; CATHELICIDIN ANTIMICROBIAL PEPTIDE LL 37; CATHEPSIN B; CD11B ANTIGEN; CHEMOKINE RECEPTOR CCR2; CHEMOKINE RECEPTOR CX3CR1; COMPLEMENT COMPONENT C1Q; COMPLEMENT COMPONENT C5A; COMPLEMENT RECEPTOR; CORTACTIN; FICOLIN; FRACTALKINE; GELATINASE B; GRANULOCYTE COLONY STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 10; INTERLEUKIN 8; MESSENGER RNA; PENTRAXIN; PENTRAXIN 3; PLASMIN; RANTES; REACTIVE OXYGEN METABOLITE; STROMAL CELL DERIVED FACTOR 1; TRABECTEDIN; UROKINASE; VASCULOTROPIN; BETA DEFENSIN 3; CHEMOKINE RECEPTOR CXCR4; COLONY STIMULATING FACTOR 1; CXCL1 CHEMOKINE; CXCL2 CHEMOKINE; CXCL3 CHEMOKINE; EPITHELIAL DERIVED NEUTROPHIL ACTIVATING FACTOR 78; FIBROBLAST GROWTH FACTOR 2; FIBROBLAST GROWTH FACTOR RECEPTOR 1; INTERLEUKIN 12; LECTIN; LECTIN REG3BETA; MANNOSE RECEPTOR; MIGRATION STIMULATING FACTOR; SCAVENGER RECEPTOR A; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ANGIOGENESIS; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER IMMUNOTHERAPY; CANCER RADIOTHERAPY; CHINESE MEDICINE; DISTANT METASTASIS; INFLAMMATION; NEOPLASM; NEUTROPHIL; NONHUMAN; PHAGOCYTE; PRIORITY JOURNAL; TUMOR ASSOCIATED LEUKOCYTE; TUMOR MICROENVIRONMENT; ANIMAL; HUMAN; IMMUNOLOGY; MACROPHAGE; PATHOLOGY; ADAPTIVE IMMUNITY; B LYMPHOCYTE; BONE MARROW CELL; BREAST EPITHELIUM CELL; CANCER RELATED INFLAMMATION; CANCER STEM CELL; CANCER SURVIVAL; CARCINOGENESIS; CD4+ T LYMPHOCYTE; CELL DIFFERENTIATION; CELL INFILTRATION; CELL INVASION; CELL SELF-RENEWAL; COLORECTAL CANCER; COMPLEMENT ACTIVATION; ECOLOGICAL NICHE; ENDOTHELIUM CELL; EPITHELIAL MESENCHYMAL TRANSITION; HEAD AND NECK SQUAMOUS CELL CARCINOMA; HEMATOPOIETIC CELL; HUMORAL IMMUNITY; IMMUNOSUPPRESSIVE TREATMENT; INNATE IMMUNITY; INTRACELLULAR SIGNALING; KIDNEY CARCINOMA; LIVER CELL CARCINOMA; LIVER METASTASIS; LUNG ALVEOLUS CELL CARCINOMA; LYMPHANGIOGENESIS; MESENCHYMAL STEM CELL; METASTASIS; MONOCYTE; NATURAL KILLER CELL; NEUTROPHIL CHEMOTAXIS; PANCREAS CANCER; POINT MUTATION; POLARIZATION; PROTEIN EXPRESSION; TRANSCRIPTOMICS; TUMOR ASSOCIATED NEUTROPHIL; TUMOR GROWTH; UPREGULATION;

ANIMALS; HUMANS; INFLAMMATION; MACROPHAGES; NEOPLASMS; PHAGOCYTES; TUMOR MICROENVIRONMENT;

EID: 84952629667     PISSN: 0065230X     EISSN: 21625557     Source Type: Book Series    
DOI: 10.1016/bs.acr.2015.04.013     Document Type: Chapter

References (184)

1. Ai S., Cheng X.W., Inoue A., Nakamura K., Okumura K., Iguchi A., et al. Angiogenic activity of bFGF and VEGF suppressed by proteolytic cleavage by neutrophil elastase. Biochemical and Biophysical Research Communications 2007, 364:395-401.
2. Ajona D., Pajares M.J., Corrales L., Perez-Gracia J.L., Agorreta J., Lozano M.D., et al. Investigation of complement activation product C4d as a diagnostic and prognostic biomarker for lung cancer. Journal of the National Cancer Institute 2013, 105:1385-1393.
3. Ajona D., Razquin C., Pastor M.D., Pajares M.J., Garcia J., Cardenal F., et al. Elevated levels of the complement activation product C4d in bronchial fluids for the diagnosis of lung cancer. PloS One 2015, 10:e0119878.
4. Allavena P., Mantovani A. Immunology in the clinic review series; focus on cancer: Tumour-associated macrophages: Undisputed stars of the inflammatory tumour microenvironment. Clinical and Experimental Immunology 2012, 167:195-205.
5. Asgari E., Le Friec G., Yamamoto H., Perucha E., Sacks S.S., Köhl J., et al. C3a modulates IL-1β secretion in human monocytes by regulating ATP efflux and subsequent NLRP3 inflammasome activation. Blood 2013, 122:3473-3481.
6. Avraham-Davidi I., Yona S., Grunewald M., Landsman L., Cochain C., Silvestre J.S., et al. On-site education of VEGF-recruited monocytes improves their performance as angiogenic and arteriogenic accessory cells. The Journal of Experimental Medicine 2013, 210:2611-2625.
7. Bain C.C., Bravo-Blas A., Scott C.L., Gomez Perdiguero E., Geissmann F., Henri S., et al. Nature Immunology 2014, 15:929-937.
8. Balkwill F. Cancer and the chemokine network. Nature Reviews. Cancer 2004, 4:540-550.
9. Balkwill F., Mantovani A. Inflammation and cancer: Back to Virchow?. Lancet 2001, 357:539-545.
10. Bandini S., Curcio C., Macagno M., Quaglino E., Arigoni M., Lanzardo S., et al. Early onset and enhanced growth of autochthonous mammary carcinomas in C3-deficient Her2/neu transgenic mice. Oncoimmunology 2013, 2:e26137.
11. Beatty G.L., Chiorean E.G., Fishman M.P., Saboury B., Teitelbaum U.R., Sun W., et al. CD40 agonists alter tumor stroma and show efficacy against pancreatic carcinoma in mice and humans. Science 2011, 331:1612-1616.
12. Bellone S., Roque D., Cocco E., Gasparrini S., Bortolomai I., Buza N., et al. Downregulation of membrane complement inhibitors CD55 and CD59 by siRNA sensitises uterine serous carcinoma overexpressing Her2/neu to complement and antibody-dependent cell cytotoxicity in vitro: Implications for trastuzumab-based immunotherapy. British Journal of Cancer 2012, 106:1543-1550.
13. Bierie B., Moses H.L. Transforming growth factor beta (TGF-beta) and inflammation in cancer. Cytokine & Growth Factor Reviews 2010, 21:49-59.
14. Biswas S.K., Gangi L., Paul S., Schioppa T., Saccani A., Sironi M., et al. A distinct and unique transcriptional program expressed by tumor-associated macrophages (defective NF-kappaB and enhanced IRF-3/STAT1 activation). Blood 2006, 107:2112-2122.
15. Biswas S.K., Mantovani A. Macrophage plasticity and interaction with lymphocyte subsets: Cancer as a paradigm. Nature Immunology 2010, 11:889-896.
16. Bjorge L., Hakulinen J., Vintermyr O.K., Jarva H., Jensen T.S., Iversen O.E., et al. Ascitic complement system in ovarian cancer. British Journal of Cancer 2005, 92:895-905.
17. Bohlson S.S., O'Conner S.D., Hulsebus H.J., Ho M.-M., Fraser D.A. Complement, C1q, and C1q-related molecules regulate macrophage polarization. Frontiers in Immunology 2014, 5:402.
18. Bohrer L.R., Schwertfeger K.L. Macrophages promote fibroblast growth factor receptor-driven tumor cell migration and invasion in a CXCR2-dependent manner. Molecular Cancer Research: MCR 2012, 10:1294-1305.
19. Bonavita E., Gentile S., Rubino M., Maina V., Papait R., Kunderfranco P., et al. PTX3 is an extrinsic oncosuppressor regulating complement-dependent inflammation in cancer. Cell 2015, 160:700-714.
20. Bottazzi B., Erba E., Nobili N., Fazioli F., Rambaldi A., Mantovani A. A paracrine circuit in the regulation of the proliferation of macrophages infiltrating murine sarcomas. Journal of Immunology 1990, 144:2409-2412.
21. Bottazzi B., Polentarutti N., Acero R., Balsari A., Boraschi D., Ghezzi P., et al. Regulation of the macrophage content of neoplasms by chemoattractants. Science 1983, 220:210-212.
22. Bottazzi B., Vouret-Craviari V., Bastone A., De Gioia L., Matteucci C., Peri G., et al. Multimer formation and ligand recognition by the long pentraxin PTX3. Similarities and differences with the short pentraxins C-reactive protein and serum amyloid P component. The Journal of Biological Chemistry 1997, 272:32817-32823.
23. Braunschweig A., Jozsi M. Human pentraxin 3 binds to the complement regulator c4b-binding protein. PloS One 2011, 6:e23991.
24. Bronte V., Zanovello P. Regulation of immune responses by L-arginine metabolism. Nature Reviews. Immunology 2005, 5:641-654.
25. Bu X., Zheng Z., Wang C., Yu Y. Significance of C4d deposition in the follicular lymphoma and MALT lymphoma and their relationship with follicular dendritic cells. Pathology, Research and Practice 2007, 203:163-167.
26. Camus M., Tosolini M., Mlecnik B., Pages F., Kirilovsky A., Berger A., et al. Coordination of intratumoral immune reaction and human colorectal cancer recurrence. Cancer Research 2009, 69:2685-2693.
27. Caruso R.A., Bellocco R., Pagano M., Bertoli G., Rigoli L., Inferrera C. Prognostic value of intratumoral neutrophils in advanced gastric carcinoma in a high-risk area in northern Italy. Modern Pathology: An Official Journal of the United States and Canadian Academy of Pathology, Inc 2002, 15:831-837.
28. Casazza A., Laoui D., Wenes M., Rizzolio S., Bassani N., Mambretti M., et al. Impeding macrophage entry into hypoxic tumor areas by Sema3A/Nrp1 signaling blockade inhibits angiogenesis and restores antitumor immunity. Cancer Cell 2013, 24:695-709.
29. Casbon A.J., Reynaud D., Park C., Khuc E., Gan D.D., Schepers K., et al. Invasive breast cancer reprograms early myeloid differentiation in the bone marrow to generate immunosuppressive neutrophils. Proceedings of the National Academy of Sciences of the United States of America 2015, 112:E566-E575.
30. Cassatella M.A. On the production of TNF-related apoptosis-inducing ligand (TRAIL/Apo-2L) by human neutrophils. Journal of Leukocyte Biology 2006, 79:1140-1149.
31. Chang C.I., Liao J.C., Kuo L. Macrophage arginase promotes tumor cell growth and suppresses nitric oxide-mediated tumor cytotoxicity. Cancer Research 2001, 61:1100-1106.
32. Chen C., Qu Q.X., Shen Y., Mu C.Y., Zhu Y.B., Zhang X.G., et al. Induced expression of B7-H4 on the surface of lung cancer cell by the tumor-associated macrophages: A potential mechanism of immune escape. Cancer Letters 2012, 317:99-105.
33. Chen C., Shen Y., Qu Q.X., Chen X.Q., Zhang X.G., Huang J.A. Induced expression of B7-H3 on the lung cancer cells and macrophages suppresses T-cell mediating anti-tumor immune response. Experimental Cell Research 2013, 319:96-102.
34. Christofori G. New signals from the invasive front. Nature 2006, 441:444-450.
35. Colegio O.R., Chu N.Q., Szabo A.L., Chu T., Rhebergen A.M., Jairam V., et al. Functional polarization of tumour-associated macrophages by tumour-derived lactic acid. Nature 2014, 513:559-563.
36. Cools-Lartigue J., Spicer J., McDonald B., Gowing S., Chow S., Giannias B., et al. Neutrophil extracellular traps sequester circulating tumor cells and promote metastasis. The Journal of Clinical Investigation 2013, 123:3446-3458.
37. Cortez-Retamozo V., Etzrodt M., Newton A., Rauch P.J., Chudnovskiy A., Berger C., et al. Origins of tumor-associated macrophages and neutrophils. Proceedings of the National Academy of Sciences of the United States of America 2012, 109:2491-2496.
38. Cortez-Retamozo V., Etzrodt M., Newton A., Ryan R., Pucci F., Sio S.W., et al. Angiotensin II drives the production of tumor-promoting macrophages. Immunity 2013, 38:296-308.
39. Coussens L.M., Zitvogel L., Palucka A.K. Neutralizing tumor-promoting chronic inflammation: A magic bullet?. Science 2013, 339:286-291.
40. De Palma M., Lewis C.E. Macrophage regulation of tumor responses to anticancer therapies. Cancer Cell 2013, 23:277-286.
41. de Visser K.E., Korets L.V., Coussens L.M. Early neoplastic progression is complement independent. Neoplasia 2004, 6:768-776.
42. Deban L., Jarva H., Lehtinen M.J., Bottazzi B., Bastone A., Doni A., et al. Binding of the long pentraxin PTX3 to factor H: Interacting domains and function in the regulation of complement activation. Journal of Immunology 2008, 181:8433-8440.
43. De Kleer I., Willems F., Lambrecht B., Goriely S. Frontiers in Immunology 2014, 5:423.
44. DeNardo D.G., Barreto J.B., Andreu P., Vasquez L., Tawfik D., Kolhatkar N., et al. CD4(+) T cells regulate pulmonary metastasis of mammary carcinomas by enhancing protumor properties of macrophages. Cancer Cell 2009, 16:91-102.
45. Doedens A.L., Stockmann C., Rubinstein M.P., Liao D., Zhang N., DeNardo D.G., et al. Macrophage expression of hypoxia-inducible factor-1 alpha suppresses T-cell function and promotes tumor progression. Cancer Research 2010, 70:7465-7475.
46. Doni A., Garlanda C., Bottazzi B., Meri S., Garred P., Mantovani A. Interactions of the humoral pattern recognition molecule PTX3 with the complement system. Immunobiology 2012, 217:1122-1128.
47. Donskov F. Immunomonitoring and prognostic relevance of neutrophils in clinical trials. Seminars in Cancer Biology 2013, 23:200-207.
48. Duluc D., Corvaisier M., Blanchard S., Catala L., Descamps P., Gamelin E., et al. Interferon-gamma reverses the immunosuppressive and protumoral properties and prevents the generation of human tumor-associated macrophages. International Journal of Cancer. Journal International du Cancer 2009, 125:367-373.
49. Dumitru C.A., Bankfalvi A., Gu X., Eberhardt W.E., Zeidler R., Lang S., et al. Neutrophils activate tumoral CORTACTIN to enhance progression of orohypopharynx carcinoma. Frontiers in Immunology 2013, 4:33.
50. Dumitru C.A., Gholaman H., Trellakis S., Bruderek K., Dominas N., Gu X., et al. Tumor-derived macrophage migration inhibitory factor modulates the biology of head and neck cancer cells via neutrophil activation. International Journal of Cancer. Journal International du Cancer 2011, 129:859-869.
51. Ebrahem Q., Chaurasia S.S., Vasanji A., Qi J.H., Klenotic P.A., Cutler A., et al. Cross-talk between vascular endothelial growth factor and matrix metalloproteinases in the induction of neovascularization in vivo. The American Journal of Pathology 2010, 176:496-503.
52. Edwards J.P., Emens L.A. The multikinase inhibitor sorafenib reverses the suppression of IL-12 and enhancement of IL-10 by PGE(2) in murine macrophages. International Immunopharmacology 2010, 10:1220-1228.
53. Eruslanov E.B., Bhojnagarwala P.S., Quatromoni J.G., Stephen T.L., Ranganathan A., Deshpande C., et al. Tumor-associated neutrophils stimulate T cell responses in early-stage human lung cancer. The Journal of Clinical Investigation 2014, 124:5466-5480.
54. Fang C., Zhang X., Miwa T., Song W.-C. Complement promotes the development of inflammatory T-helper 17 cells through synergistic interaction with Toll-like receptor signaling and interleukin-6 production. Blood 2009, 114:1005-1015.
55. Fossati G., Ricevuti G., Edwards S.W., Walker C., Dalton A., Rossi M.L. Neutrophil infiltration into human gliomas. Acta Neuropathologica 1999, 98:349-354.
56. Franklin R.A., Liao W., Sarkar A., Kim M.V., Bivona M.R., Liu K., et al. The cellular and molecular origin of tumor-associated macrophages. Science 2014, 344:921-925.
57. Fridlender Z.G., Sun J., Kim S., Kapoor V., Cheng G., Ling L., et al. Polarization of tumor-associated neutrophil phenotype by TGF-beta: "N1" versus "N2" TAN. Cancer Cell 2009, 16:183-194.
58. Fridlender Z.G., Sun J., Mishalian I., Singhal S., Cheng G., Kapoor V., et al. Transcriptomic analysis comparing tumor-associated neutrophils with granulocytic myeloid-derived suppressor cells and normal neutrophils. PloS One 2012, 7:e31524.
59. Gabrilovich D.I., Ostrand-Rosenberg S., Bronte V. Coordinated regulation of myeloid cells by tumours. Nature Reviews. Immunology 2012, 12:253-268.
60. Galon J., Costes A., Sanchez-Cabo F., Kirilovsky A., Mlecnik B., Lagorce-Pages C., et al. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science 2006, 313:1960-1964.
61. Gelderman K.A., Tomlinson S., Ross G.D., Gorter A. Complement function in mAb-mediated cancer immunotherapy. Trends in Immunology 2004, 25:158-164.
62. Germano G., Frapolli R., Belgiovine C., Anselmo A., Pesce S., Liguori M., et al. Role of macrophage targeting in the anti-tumor activity of Trabectedin. Cancer Cell 2013, 23:249-262.
63. Gironella M., Calvo C., Fernandez A., Closa D., Iovanna J.L., Rosello-Catafau J., et al. Reg3beta deficiency impairs pancreatic tumor growth by skewing macrophage polarization. Cancer Research 2013, 73:5682-5694.
64. Gocheva V., Wang H.W., Gadea B.B., Shree T., Hunter K.E., Garfall A.L., et al. IL-4 induces cathepsin protease activity in tumor-associated macrophages to promote cancer growth and invasion. Genes & Development 2010, 24:241-255.
65. Gomez Perdiguero E., Klapproth K., Schulz C., Busch K., Azzoni E., Crozet L., et al. Nature 2015, 518:547-551.
66. Gorelik E., Wiltrout R.H., Brunda M.J., Holden H.T., Herberman R.B. Augmentation of metastasis formation by thioglycollate-elicited macrophages. International Journal of Cancer. Journal International du Cancer 1982, 29:575-581.
67. Gout E., Moriscot C., Doni A., Dumestre-Perard C., Lacroix M., Perard J., et al. M-ficolin interacts with the long pentraxin PTX3: A novel case of cross-talk between soluble pattern-recognition molecules. Journal of Immunology 2011, 186:5815-5822.
68. Granata F., Frattini A., Loffredo S., Staiano R.I., Petraroli A., Ribatti D., et al. Production of vascular endothelial growth factors from human lung macrophages induced by group IIA and group X secreted phospholipases A2. Journal of Immunology 2010, 184:5232-5241.
69. Granot Z., Henke E., Comen E.A., King T.A., Norton L., Benezra R. Tumor entrained neutrophils inhibit seeding in the premetastatic lung. Cancer Cell 2011, 20:300-314.
70. Grenz S., Naschberger E., Merkel S., Britzen-Laurent N., Schaal U., Konrad A., et al. IFN-gamma-driven intratumoral microenvironment exhibits superior prognostic effect compared with an IFN-alpha-driven microenvironment in patients with colon carcinoma. The American Journal of Pathology 2013, 183:1897-1909.
71. Grosse-Steffen T., Giese T., Giese N., Longerich T., Schirmacher P., Hansch G.M., et al. Epithelial-to-mesenchymal transition in pancreatic ductal adenocarcinoma and pancreatic tumor cell lines: The role of neutrophils and neutrophil-derived elastase. Clinical & Developmental Immunology 2012, 2012:720768.
72. Gungor N., Knaapen A.M., Munnia A., Peluso M., Haenen G.R., Chiu R.K., et al. Genotoxic effects of neutrophils and hypochlorous acid. Mutagenesis 2010, 25:149-154.
73. Hagemann T., Wilson J., Burke F., Kulbe H., Li N.F., Pluddemann A., et al. Ovarian cancer cells polarize macrophages toward a tumor-associated phenotype. Journal of Immunology 2006, 176:5023-5032.
74. Hanahan D., Weinberg R.A. Hallmarks of cancer: The next generation. Cell 2011, 144:646-674.
75. Hewish M., Lord C.J., Martin S.A., Cunningham D., Ashworth A. Mismatch repair deficient colorectal cancer in the era of personalized treatment. Nature Reviews. Clinical Oncology 2010, 7:197-208.
76. Hirt C., Eppenberger-Castori S., Sconocchia G., Iezzi G., Tornillo L., Terracciano L., et al. Colorectal carcinoma infiltration by myeloperoxidase-expressing neutrophil granulocytes is associated with favorable prognosis. Oncoimmunology 2013, 2:e25990.
77. Hörl S., Bánki Z., Huber G., Ejaz A., Windisch D., Muellauer B., et al. Reduction of complement factor H binding to CLL cells improves the induction of rituximab-mediated complement-dependent cytotoxicity. Leukemia 2013, 27:2200-2208.
78. Hotchkiss K.A., Ashton A.W., Klein R.S., Lenzi M.L., Zhu G.H., Schwartz E.L. Mechanisms by which tumor cells and monocytes expressing the angiogenic factor thymidine phosphorylase mediate human endothelial cell migration. Cancer Research 2003, 63:527-533.
79. Houghton A.M., Rzymkiewicz D.M., Ji H., Gregory A.D., Egea E.E., Metz H.E., et al. Neutrophil elastase-mediated degradation of IRS-1 accelerates lung tumor growth. Nature Medicine 2010, 16:219-223.
80. Huang S., Van Arsdall M., Tedjarati S., McCarty M., Wu W., Langley R., et al. Contributions of stromal metalloproteinase-9 to angiogenesis and growth of human ovarian carcinoma in mice. Journal of the National Cancer Institute 2002, 94:1134-1142.
81. Huh S.J., Liang S., Sharma A., Dong C., Robertson G.P. Transiently entrapped circulating tumor cells interact with neutrophils to facilitate lung metastasis development. Cancer Research 2010, 70:6071-6082.
82. Ijichi H., Chytil A., Gorska A.E., Aakre M.E., Bierie B., Tada M., et al. Inhibiting Cxcr2 disrupts tumor-stromal interactions and improves survival in a mouse model of pancreatic ductal adenocarcinoma. The Journal of Clinical Investigation 2011, 121:4106-4117.
83. Imai Y., Kubota Y., Yamamoto S., Tsuji K., Shimatani M., Shibatani N., et al. Neutrophils enhance invasion activity of human cholangiocellular carcinoma and hepatocellular carcinoma cells: An in vitro study. Journal of Gastroenterology and Hepatology 2005, 20:287-293.
84. Inforzato A., Doni A., Barajon I., Leone R., Garlanda C., Bottazzi B., et al. PTX3 as a paradigm for the interaction of pentraxins with the complement system. Seminars in Immunology 2013, 25:79-85.
85. Jablonska J., Leschner S., Westphal K., Lienenklaus S., Weiss S. Neutrophils responsive to endogenous IFN-beta regulate tumor angiogenesis and growth in a mouse tumor model. The Journal of Clinical Investigation 2010, 120:1151-1164.
86. Jamieson T., Clarke M., Steele C.W., Samuel M.S., Neumann J., Jung A., et al. Inhibition of CXCR2 profoundly suppresses inflammation-driven and spontaneous tumorigenesis. The Journal of Clinical Investigation 2012, 122:3127-3144.
87. Jensen H.K., Donskov F., Marcussen N., Nordsmark M., Lundbeck F., von der Maase H. Presence of intratumoral neutrophils is an independent prognostic factor in localized renal cell carcinoma. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology 2009, 27:4709-4717.
88. Jin G., Kawsar H.I., Hirsch S.A., Zeng C., Jia X., Feng Z., et al. An antimicrobial peptide regulates tumor-associated macrophage trafficking via the chemokine receptor CCR2, a model for tumorigenesis. PloS One 2010, 5:e10993.
89. Joyce J.A., Pollard J.W. Microenvironmental regulation of metastasis. Nature Reviews. Cancer 2009, 9:239-252.
90. Kadoch C., Li J., Wong V.S., Chen L., Cha S., Munster P., et al. Complement activation and intraventricular rituximab distribution in recurrent central nervous system lymphoma. Clinical Cancer Research: An Official Journal of the American Association for Cancer Research 2014, 20:1029-1041.
91. Katara G.K., Jaiswal M.K., Kulshrestha A., Kolli B., Gilman-Sachs A., Beaman K.D. Tumor-associated vacuolar ATPase subunit promotes tumorigenic characteristics in macrophages. Oncogene 2014, 33:5649-5654.
92. Keane M.P., Belperio J.A., Xue Y.Y., Burdick M.D., Strieter R.M. Depletion of CXCR2 inhibits tumor growth and angiogenesis in a murine model of lung cancer. Journal of Immunology 2004, 172:2853-2860.
93. Keeley E.C., Mehrad B., Strieter R.M. CXC chemokines in cancer angiogenesis and metastases. Advances in Cancer Research 2010, 106:91-111.
94. Kemp T.J., Ludwig A.T., Earel J.K., Moore J.M., Vanoosten R.L., Moses B., et al. Neutrophil stimulation with Mycobacterium bovis bacillus Calmette-Guerin (BCG) results in the release of functional soluble TRAIL/Apo-2L. Blood 2005, 106:3474-3482.
95. Kryczek I., Zou L., Rodriguez P., Zhu G., Wei S., Mottram P., et al. B7-H4 expression identifies a novel suppressive macrophage population in human ovarian carcinoma. The Journal of Experimental Medicine 2006, 203:871-881.
96. Kuang D.M., Zhao Q., Peng C., Xu J., Zhang J.P., Wu C., et al. Activated monocytes in peritumoral stroma of hepatocellular carcinoma foster immune privilege and disease progression through PD-L1. The Journal of Experimental Medicine 2009, 206:1327-1337.
97. Kuang D.M., Zhao Q., Wu Y., Peng C., Wang J., Xu Z., et al. Peritumoral neutrophils link inflammatory response to disease progression by fostering angiogenesis in hepatocellular carcinoma. Journal of Hepatology 2011, 54:948-955.
98. Laoui D., Van Overmeire E., Di Conza G., Aldeni C., Keirsse J., Morias Y., et al. Tumor hypoxia does not drive differentiation of tumor-associated macrophages but rather fine-tunes the M2-like macrophage population. Cancer Research 2014, 74:24-30.
99. Lazennec G., Richmond A. Chemokines and chemokine receptors: New insights into cancer-related inflammation. Trends in Molecular Medicine 2010, 16:133-144.
100. Li D., Wang X., Wu J.L., Quan W.Q., Ma L., Yang F., et al. Tumor-produced versican V1 enhances hCAP18/LL-37 expression in macrophages through activation of TLR2 and vitamin D3 signaling to promote ovarian cancer progression in vitro. PloS One 2013, 8:e56616.
101. Lin E.Y., Gouon-Evans V., Nguyen A.V., Pollard J.W. The macrophage growth factor CSF-1 in mammary gland development and tumor progression. Journal of Mammary Gland Biology and Neoplasia 2002, 7:147-162.
102. Lin J.Y., Li X.Y., Tadashi N., Dong P. Clinical significance of tumor-associated macrophage infiltration in supraglottic laryngeal carcinoma. Chinese Journal of Cancer 2011, 30:280-286.
103. Linde N., Lederle W., Depner S., van Rooijen N., Gutschalk C.M., Mueller M.M. Vascular endothelial growth factor-induced skin carcinogenesis depends on recruitment and alternative activation of macrophages. The Journal of Pathology 2012, 227:17-28.
104. Ma Y.J., Doni A., Romani L., Jurgensen H.J., Behrendt N., Mantovani A., et al. Ficolin-1-PTX3 complex formation promotes clearance of altered self-cells and modulates IL-8 production. Journal of Immunology 2013, 191:1324-1333.
105. Mantovani A. The yin-yang of tumor-associated neutrophils. Cancer Cell 2009, 16:173-174.
106. Mantovani A., Allavena P. The interaction of anticancer therapies with tumor-associated macrophages. The Journal of Experimental Medicine 2015, 212:435-445. 10.1084/jem.20150295.
107. Mantovani A., Allavena P., Sica A., Balkwill F. Cancer-related inflammation. Nature 2008, 454:436-444.
108. Mantovani A., Allavena P., Sozzani S., Vecchi A., Locati M., Sica A. Chemokines in the recruitment and shaping of the leukocyte infiltrate of tumors. Seminars in Cancer Biology 2004, 14:155-160.
109. Mantovani A., Bottazzi B., Colotta F., Sozzani S., Ruco L. The origin and function of tumor-associated macrophages. Immunology Today 1992, 13:265-270.
110. Mantovani A., Cassatella M.A., Costantini C., Jaillon S. Neutrophils in the activation and regulation of innate and adaptive immunity. Nature Reviews. Immunology 2011, 11:519-531.
111. Mantovani A., Sica A. Macrophages, innate immunity and cancer: Balance, tolerance, and diversity. Current Opinion in Immunology 2010, 22:231-237.
112. Mantovani A., Sozzani S., Locati M., Allavena P., Sica A. Macrophage polarization: Tumor-associated macrophages as a paradigm for polarized M2 mononuclear phagocytes. Trends in Immunology 2002, 23:549-555.
113. Markiewski M.M., DeAngelis R.A., Benencia F., Ricklin-Lichtsteiner S.K., Koutoulaki A., Gerard C., et al. Modulation of the antitumor immune response by complement. Nature Immunology 2008, 9:1225-1235.
114. Matsui A., Yokoo H., Negishi Y., Endo-Takahashi Y., Chun N.A., Kadouchi I., et al. CXCL17 expression by tumor cells recruits CD11b+Gr1 high F4/80-cells and promotes tumor progression. PloS One 2012, 7:e44080.
115. McGovern N., Schlitzer A., Gunawan M., Jardine L., Shin A., Poyner E.,V., et al. Immunity 2014, 41:465-477.
116. Middleton O., Cosimo E., Dobbin E., McCaig A.M., Clarke C., Brant A.M., et al. Complement deficiencies limit CD20 monoclonal antibody treatment efficacy in CLL. Leukemia 2015, 29:107-114.
117. Mittendorf E.A., Alatrash G., Qiao N., Wu Y., Sukhumalchandra P., St John L.S., et al. Breast cancer cell uptake of the inflammatory mediator neutrophil elastase triggers an anticancer adaptive immune response. Cancer Research 2012, 72:3153-3162.
118. Molawi K., Wolf Y., Kandalla P.K., Favret J., Hagemeyer N., Frenzel K., et al. The Journal of Experimental Medicine 2014, 211:2151-2158.
119. Mosser D.M., Edwards J.P. Exploring the full spectrum of macrophage activation. Nature Reviews. Immunology 2008, 8:958-969.
120. Movahedi K., Laoui D., Gysemans C., Baeten M., Stange G., Van den Bossche J., et al. Different tumor microenvironments contain functionally distinct subsets of macrophages derived from Ly6C(high) monocytes. Cancer Research 2010, 70:5728-5739.
121. Murdoch C., Giannoudis A., Lewis C.E. Mechanisms regulating the recruitment of macrophages into hypoxic areas of tumors and other ischemic tissues. Blood 2004, 104:2224-2234.
122. Murray P.J., Allen J.E., Biswas S.K., Fisher E.A., Gilroy D.W., Goerdt S., et al. Macrophage activation and polarization: Nomenclature and experimental guidelines. Immunity 2014, 41:14-20.
123. Nagakawa Y., Aoki T., Kasuya K., Tsuchida A., Koyanagi Y. Histologic features of venous invasion, expression of vascular endothelial growth factor and matrix metalloproteinase-2 and matrix metalloproteinase-9, and the relation with liver metastasis in pancreatic cancer. Pancreas 2002, 24:169-178.
124. Naschberger E., Croner R.S., Merkel S., Dimmler A., Tripal P., Amann K.U., et al. Angiostatic immune reaction in colorectal carcinoma: Impact on survival and perspectives for antiangiogenic therapy. International Journal of Cancer. Journal International du Cancer 2008, 123:2120-2129.
125. Neyen C., Pluddemann A., Mukhopadhyay S., Maniati E., Bossard M., Gordon S., et al. Macrophage scavenger receptor a promotes tumor progression in murine models of ovarian and pancreatic cancer. Journal of Immunology 2013, 190:3798-3805.
126. Ning C., Li Y.Y., Wang Y., Han G.C., Wang R.X., Xiao H., et al. Complement activation promotes colitis-associated carcinogenesis through activating intestinal IL-1β/IL-17A axis. Mucosal Immunology 2015, 2015 March 4. 10.1038/mi.2015.18.
127. Noy R., Pollard J.W. Tumor-associated macrophages: From mechanisms to therapy. Immunity 2014, 41:49-61.
128. Nozaki M., Raisler B.J., Sakurai E., Sarma J.V., Barnum S.R., Lambris J.D., et al. Drusen complement components C3a and C5a promote choroidal neovascularization. Proceedings of the National Academy of Sciences of the United States of America 2006, 103:2328-2333.
129. Nozawa H., Chiu C., Hanahan D. Infiltrating neutrophils mediate the initial angiogenic switch in a mouse model of multistage carcinogenesis. Proceedings of the National Academy of Sciences of the United States of America 2006, 103:12493-12498.
130. Okemefuna A.I., Nan R., Miller A., Gor J., Perkins S.J. Complement factor H binds at two independent sites to C-reactive protein in acute phase concentrations. The Journal of Biological Chemistry 2010, 285:1053-1065.
131. Pasinetti G.M., Tocco G., Sakhi S., Musleh W.D., DeSimoni M.G., Mascarucci P., et al. Hereditary deficiencies in complement C5 are associated with intensified neurodegenerative responses that implicate new roles for the C-system in neuronal and astrocytic functions. Neurobiology of Disease 1996, 3:197-204.
132. Piao C., Cai L., Qiu S., Jia L., Song W., Du J. Complement 5a enhances hepatic metastases of colon cancer via monocyte chemoattractant protein-1-mediated inflammatory cell infiltration. Journal of Biological Chemistry 2015, 290:10667-10676. 2015 March 4, pii: jbc.M114.612622.
133. Pio R., Corrales L., Lambris J. The role of complement in tumor growth. Tumor microenvironment and cellular stress 2014, 229-262. Springer, New York. C. Koumenis, E. Hammond, A. Giaccia (Eds.).
134. Qing W., Fang W.Y., Ye L., Shen L.Y., Zhang X.F., Fei X.C., et al. Density of tumor-associated macrophages correlates with lymph node metastasis in papillary thyroid carcinoma. Thyroid: Official Journal of the American Thyroid Association 2012, 22:905-910.
135. Queen M.M., Ryan R.E., Holzer R.G., Keller-Peck C.R., Jorcyk C.L. Breast cancer cells stimulate neutrophils to produce oncostatin M: Potential implications for tumor progression. Cancer Research 2005, 65:8896-8904.
136. Rao H.L., Chen J.W., Li M., Xiao Y.B., Fu J., Zeng Y.X., et al. Increased intratumoral neutrophil in colorectal carcinomas correlates closely with malignant phenotype and predicts patients' adverse prognosis. PloS One 2012, 7:e30806.
137. Reed J.R., Stone M.D., Beadnell T.C., Ryu Y., Griffin T.J., Schwertfeger K.L. Fibroblast growth factor receptor 1 activation in mammary tumor cells promotes macrophage recruitment in a CX3CL1-dependent manner. PloS One 2012, 7:e45877.
138. Reid M.D., Basturk O., Thirabanjasak D., Hruban R.H., Klimstra D.S., Bagci P., et al. Tumor-infiltrating neutrophils in pancreatic neoplasia. Modern Pathology: An Official Journal of the United States and Canadian Academy of Pathology, Inc. 2011, 24:1612-1619.
139. Ricklin D., Hajishengallis G., Yang K., Lambris J.D. Complement: A key system for immune surveillance and homeostasis. Nature Immunology 2010, 11:785-797.
140. Ricklin D., Lambris J.D. Complement in immune and inflammatory disorders: Pathophysiological mechanisms. Journal of Immunology 2013, 190:3831-3838.
141. Rodriguez P.C., Ernstoff M.S., Hernandez C., Atkins M., Zabaleta J., Sierra R., et al. Arginase I-producing myeloid-derived suppressor cells in renal cell carcinoma are a subpopulation of activated granulocytes. Cancer Research 2009, 69:1553-1560.
142. Rozel S., Galban C.J., Nicolay K., Lee K.C., Sud S., Neeley C., et al. Synergy between anti-CCL2 and docetaxel as determined by DW-MRI in a metastatic bone cancer model. Journal of Cellular Biochemistry 2009, 107:58-64.
143. Ruffell B., Affara N.I., Coussens L.M. Differential macrophage programming in the tumor microenvironment. Trends in Immunology 2012, 33:119-126.
144. Rutkowski M.J., Sughrue M.E., Kane A.J., Mills S.A., Parsa A.T. Cancer and the complement cascade. Molecular Cancer Research: MCR 2010, 8:1453-1465.
145. Sagiv J.Y., Michaeli J., Assi S., Mishalian I., Kisos H., Levy L., et al. Phenotypic diversity and plasticity in circulating neutrophil subpopulations in cancer. Cell Reports 2015, 10:562-573.
146. Scapini P., Morini M., Tecchio C., Minghelli S., Di Carlo E., Tanghetti E., et al. CXCL1/macrophage inflammatory protein-2-induced angiogenesis in vivo is mediated by neutrophil-derived vascular endothelial growth factor-A. Journal of Immunology 2004, 172:5034-5040.
147. Scapini P., Nesi L., Morini M., Tanghetti E., Belleri M., Noonan D., et al. Generation of biologically active angiostatin kringle 1-3 by activated human neutrophils. Journal of Immunology 2002, 168:5798-5804.
148. Schmidt T., Carmeliet P. Blood-vessel formation: Bridges that guide and unite. Nature 2010, 465:697-699.
149. Schmielau J., Finn O.J. Activated granulocytes and granulocyte-derived hydrogen peroxide are the underlying mechanism of suppression of t-cell function in advanced cancer patients. Cancer Research 2001, 61:4756-4760.
150. Schoppmann S.F., Horvat R., Birner P. Lymphatic vessels and lymphangiogenesis in female cancer: Mechanisms, clinical impact and possible implications for anti-lymphangiogenic therapies (Review). Oncology Reports 2002, 9:455-460.
151. Shand F.H.W., Ueha S., Otsuji M., Koid S.S., Shichino S., Tsukui T., et al. Proceedings of the National Academy of Sciences 2014, 111:7771-7776.
152. Shojaei F., Singh M., Thompson J.D., Ferrara N. Role of Bv8 in neutrophil-dependent angiogenesis in a transgenic model of cancer progression. Proceedings of the National Academy of Sciences of the United States of America 2008, 105:2640-2645.
153. Shojaei F., Wu X., Qu X., Kowanetz M., Yu L., Tan M., et al. G-CSF-initiated myeloid cell mobilization and angiogenesis mediate tumor refractoriness to anti-VEGF therapy in mouse models. Proceedings of the National Academy of Sciences of the United States of America 2009, 106:6742-6747.
154. Shojaei F., Wu X., Zhong C., Yu L., Liang X.H., Yao J., et al. Bv8 regulates myeloid-cell-dependent tumour angiogenesis. Nature 2007, 450:825-831.
155. Sica A., Mantovani A. Macrophage plasticity and polarization: In vivo veritas. The Journal of Clinical Investigation 2012, 122:787-795.
156. Sica A., Saccani A., Bottazzi B., Polentarutti N., Vecchi A., van Damme J., et al. Autocrine production of IL-10 mediates defective IL-12 production and NF-kappa B activation in tumor-associated macrophages. Journal of Immunology 2000, 164:762-767.
157. Sjoberg A.P., Trouw L.A., McGrath F.D., Hack C.E., Blom A.M. Regulation of complement activation by C-reactive protein: Targeting of the inhibitory activity of C4b-binding protein. Journal of Immunology 2006, 176:7612-7620.
158. Solinas G., Schiarea S., Liguori M., Fabbri M., Pesce S., Zammataro L., et al. Tumor-conditioned macrophages secrete migration-stimulating factor: A new marker for M2-polarization, influencing tumor cell motility. Journal of Immunology 2010, 185:642-652.
159. Solito S., Falisi E., Diaz-Montero C.M., Doni A., Pinton L., Rosato A., et al. A human promyelocytic-like population is responsible for the immune suppression mediated by myeloid-derived suppressor cells. Blood 2011, 118:2254-2265.
160. Stetler-Stevenson W.G., Yu A.E. Proteases in invasion: Matrix metalloproteinases. Seminars in Cancer Biology 2001, 11:143-152.
161. Tanaka H., Ito T., Kyo T., Kimura A. Treatment with IFNalpha in vivo up-regulates serum-soluble TNF-related apoptosis inducing ligand (sTRAIL) levels and TRAIL mRNA expressions in neutrophils in chronic myelogenous leukemia patients. European Journal of Haematology 2007, 78:389-398.
162. Tecchio C., Huber V., Scapini P., Calzetti F., Margotto D., Todeschini G., et al. IFNalpha-stimulated neutrophils and monocytes release a soluble form of TNF-related apoptosis-inducing ligand (TRAIL/Apo-2 ligand) displaying apoptotic activity on leukemic cells. Blood 2004, 103:3837-3844.
163. Tecchio C., Scapini P., Pizzolo G., Cassatella M.A. On the cytokines produced by human neutrophils in tumors. Seminars in Cancer Biology 2013, 23:159-170.
164. Trellakis S., Bruderek K., Dumitru C.A., Gholaman H., Gu X., Bankfalvi A., et al. Polymorphonuclear granulocytes in human head and neck cancer: Enhanced inflammatory activity, modulation by cancer cells and expansion in advanced disease. International Journal of Cancer. Journal International du Cancer 2011, 129:2183-2193.
165. Trellakis S., Farjah H., Bruderek K., Dumitru C.A., Hoffmann T.K., Lang S., et al. Peripheral blood neutrophil granulocytes from patients with head and neck squamous cell carcinoma functionally differ from their counterparts in healthy donors. International Journal of Immunopathology and Pharmacology 2011, 24:683-693.
166. Tymoszuk P., Evens H., Marzola V., Wachowicz K., Wasmer M.H., Datta S., et al. In situ proliferation contributes to accumulation of tumor-associated macrophages in spontaneous mammary tumors. European Journal of Immunology 2014, 44:2247-2262.
167. Ueno T., Toi M., Saji H., Muta M., Bando H., Kuroi K., et al. Significance of macrophage chemoattractant protein-1 in macrophage recruitment, angiogenesis, and survival in human breast cancer. Clinical Cancer Research 2000, 8:3282-3289.
168. Vadrevu S.K., Chintala N.K., Sharma S.K., Sharma P., Cleveland C., Riediger L., et al. Complement C5a receptor facilitates cancer metastasis by altering T-cell responses in the metastatic niche. Cancer Research 2014, 74:3454-3465.
169. Vasiljeva O., Papazoglou A., Kruger A., Brodoefel H., Korovin M., Deussing J., et al. Tumor cell-derived and macrophage-derived cathepsin B promotes progression and lung metastasis of mammary cancer. Cancer Research 2006, 66:5242-5250.
170. Wang F.Q., So J., Reierstad S., Fishman D.A. Matrilysin (MMP-7) promotes invasion of ovarian cancer cells by activation of progelatinase. International Journal of Cancer. Journal International du Cancer 2005, 114:19-31.
171. Wang X.F., Wang H.S., Zhang F., Guo Q., Wang H., Wang K.F., et al. Nodal promotes the generation of M2-like macrophages and downregulates the expression of IL-12. European Journal of Immunology 2014, 44:173-183.
172. Wang R., Zhang J., Chen S., Lu M., Luo X., Yao S., et al. Tumor-associated macrophages provide a suitable microenvironment for non-small lung cancer invasion and progression. Lung Cancer 2011, 74:188-196.
173. Weitzman S.A., Weitberg A.B., Clark E.P., Stossel T.P. Phagocytes as carcinogens: Malignant transformation produced by human neutrophils. Science (New York, N.Y.) 1985, 227:1231-1233.
174. Wislez M., Rabbe N., Marchal J., Milleron B., Crestani B., Mayaud C., et al. Hepatocyte growth factor production by neutrophils infiltrating bronchioloalveolar subtype pulmonary adenocarcinoma: Role in tumor progression and death. Cancer Research 2003, 63:1405-1412.
175. Wu C.F., Andzinski L., Kasnitz N., Kroger A., Klawonn F., Lienenklaus S., et al. The lack of type I interferon induces neutrophil-mediated pre-metastatic niche formation in the mouse lung. International Journal of Cancer. Journal International du Cancer 2015, 10.1002/ijc.29444.
176. Wynn T.A., Chawla A., Pollard J.W. Nature 2013, 496:445-455.
177. Xin H., Zhang C., Herrmann A., Du Y., Figlin R., Yu H. Sunitinib inhibition of Stat3 induces renal cell carcinoma tumor cell apoptosis and reduces immunosuppressive cells. Cancer Research 2009, 69:2506-2513.
178. Ye X.Z., Xu S.L., Xin Y.H., Yu S.C., Ping Y.F., Chen L., et al. Tumor-associated microglia/macrophages enhance the invasion of glioma stem-like cells via TGF-beta1 signaling pathway. Journal of Immunology 2012, 189:444-453.
179. Youn J.I., Collazo M., Shalova I.N., Biswas S.K., Gabrilovich D.I. Characterization of the nature of granulocytic myeloid-derived suppressor cells in tumor-bearing mice. Journal of Leukocyte Biology 2012, 91:167-181.
180. Youn J.I., Gabrilovich D.I. The biology of myeloid-derived suppressor cells: The blessing and the curse of morphological and functional heterogeneity. European Journal of Immunology 2010, 40:2969-2975.
181. Ytting H., Jarle Christensen I., Thiel S., Jensenius J.C., Nielsen H.J. Serum mannan-binding lectin-associated serine protease 2 levels in colorectal cancer: Relation to recurrence and mortality. Clinical Cancer Research 2005, 11:1441-1446.
182. Zhang J., Sud S., Mizutani K., Gyetko M.R., Pienta K.J. Activation of urokinase plasminogen activator and its receptor axis is essential for macrophage infiltration in a prostate cancer mouse model. Neoplasia 2011, 13:23-30.
183. Zhao Q., Kuang D.M., Wu Y., Xiao X., Li X.F., Li T.J., et al. Activated CD69+ T cells foster immune privilege by regulating IDO expression in tumor-associated macrophages. Journal of Immunology 2012, 188:1117-1124.
184. Zhou S.L., Dai Z., Zhou Z.J., Wang X.Y., Yang G.H., Wang Z., et al. Overexpression of CXCL5 mediates neutrophil infiltration and indicates poor prognosis for hepatocellular carcinoma. Hepatology 2012, 56:2242-2254.